6195-54-6

Basic information

• Product Name: DiosMin Octaacetate
• Synonyms: DiosMin Octaacetate
• CAS NO: 6195-54-6
• Molecular Formula: C₄₄H₄₈O₂₃
• Molecular Weight: 944.84
• Product Categories: Aromatics, Oligosaccharides, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 6195-54-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: DiosMin Octaacetate(CAS DataBase Reference)
• NIST Chemistry Reference: DiosMin Octaacetate(6195-54-6)
• EPA Substance Registry System: DiosMin Octaacetate(6195-54-6)

Safety Data

• Hazardous Substances Data: 6195-54-6(Hazardous Substances Data)

Usage

Uses

Diosmin Octaacetate is an acetylated intermediate in the synthesis of Diosmin (D485200) Derivatives.

Upstream product

• 108-24-7 acetic anhydride 
• 520-27-4 diosmin 
• 520-26-3 hesperidin 

Downstream Products

• 827346-24-7 3-bromo-octaacetyldiosmin 
• 827346-30-5 3-bromodiosmetin 
• 890661-60-6 3-bromodiosmetin 7-isopropyl ether 
• 890661-62-8 3-bromodiosmetin 7,3'-dibenzyl ether 
• 890661-71-9 3-(3'',4'',5''-trimethoxyphenyl)diosmetin 7-isopropyl ether 
• 890661-67-3 3-(3'',4'',5''-trimethoxyphenyl)diosmetin 3'-benzyl-5-methyl ether 
• 890661-66-2 3-(3'',4'',5''-trimethoxyphenyl)diosmetin 7,3'-dibenzyl-5-methyl ether 
• 890661-65-1 3-(3'',4'',5''-trimethoxyphenyl)diosmetin 7,3'-dibenzyl ether 
• 827346-33-8 C₂₈H₃₁ClO₁₅ 
• 827346-25-8 3-chlorooctacetyldiosmin 
• 1415983-00-4 3-bromo-2-methoxyoctacetylhesperidin 

Relevant articles and documents

Synthesis of 5-Hydroxy-3′,4′,7-trimethoxyflavone and Related Compounds and Elucidation of Their Reversal Effects on BCRP/ABCG2-Mediated Anticancer Drug Resistance

3′,4′,7-Trimethoxyflavone (TMF) has been reported to show a potent reversal effect on drug resistance mediated by breast cancer resistance protein (BCRP)/ATP-binding cassette subfamily G member 2 (ABCG2). In this study, we designed and synthesized five derivatives with either a hydroxy group or a fluorine atom at C-5 and several kinds of capping moiety at the C-7 hydroxy group, on the same 3′,4′-dimethoxy-substituted flavone skeleton. We subsequently evaluated the efficacies of these compounds against BCRP-expressing human leukaemia K562/BCRP cells. Reversal of drug resistance was expressed as the concentration of compound causing a twofold reduction in drug sensitivity (RI50). Of the synthesized compounds, the reversal effect of 5-hydroxy-3′,4′,7-trimethoxyflavone (HTMF, RI50 7.2 nm) towards 7-ethyl-10-hydroxycamptothecin (SN-38) was stronger than that of TMF (RI50 18 nm). Fluoro-substituted 5-fluoro-3′,4′,7-trimethoxyflavone (FTMF, RI50 25 nm) and monoglycosylated 7-(β-glucosyloxy)-5-hydroxy-3′,4′-dimethoxyflavone (GOHDMF, 91 nm) also exhibited reversal effects, whereas the di- and triglycoside derivatives did not. TMF, HTMF and FTMF at 0.01–10 μm upregulated the K562/BCRP cellular accumulation of Hoechst 33342 nuclear staining dye. In addition, western blotting revealed that treatment of K562/BCRP cells with 0.1 μm TMF, HTMF or FTMT suppressed the expression of BCRP. HTMF showed the strongest inhibition of BCRP-mediated efflux and suppression of BCRP expression of the three effective synthesized flavones.

Synthesis and anti-tubulin evaluation of chromone-based analogues of combretastatins

Twenty new hybrid compounds with both combretastatin and flavone moieties were synthesized. These derivatives are classified according to the position of the trimethoxyphenyl ring at C-2 or C-3 of the chromone and presence or absence of a carbonyl as a linker between C-3 and the aryl ring. Most of these compounds were prepared from hesperidin or naringin, two natural and abundant Citrus flavonoids. Seven of these combretastatin analogues revealed anti-tubulin activity but in a medium range.